Steroid-resistant nephrotic syndrome

被引:4
|
作者
Kitamura, Akiko [2 ]
Tsukaguchi, Hiroyasu [1 ]
Maruyama, Kenichi [3 ]
Shono, Akemi [1 ]
Iijima, Kazumoto [4 ]
Kagami, Shoji [2 ]
Doi, Toshio [1 ]
机构
[1] Univ Tokushima, Sch Med, Dept Clin Biol & Med, Tokushima 7708503, Japan
[2] Univ Tokushima, Grad Sch, Dept Pediat, Tokushima 7708503, Japan
[3] Gunma Childrens Med Ctr, Dept Pediat, Gunma, Japan
[4] Natl Ctr Child Hlth & Dev, Dept Nephrol, Tokyo, Japan
基金
日本学术振兴会;
关键词
D O I
10.1038/ki.2008.297
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
CASE PRESENTATION A 5-year-old female was referred for evaluation of steroid-resistant nephrotic syndrome (SRNS). At 3 years of age, her family was concerned about the proteinuria (3+) and hematuria (2+) and brought her to the hospital for evaluation. There was no antecedent infection, fever, or rash. No family history of renal disease was noted, and her parents and her elder brother were negative for urinalysis ( Figure 1a). At the initial visit, laboratory studies revealed hypoproteinemia ( serum albumin 3.1 g/100 ml) and hyperlipidemia ( total cholesterol 282 mg/100 ml), whereas renal function was normal ( serum creatinine 0.2 mg/100 ml, and an estimated glomerular filtration rate 135 ml/min/1.73 m(2), Figure 1b, c and Table 1). On presentation to the hospital, the patient appeared normal. Physical examination was unremarkable with normal growth; the height was 98.2 cm (+0.8 s.d., 68 percentile) and weight was 13.0 kg (-0.5 s.d., 38 percentile). There was no dysmorphic features, edema, joint swelling, or hearing loss. The systemic workup including cardiovascular, neurological, and ophthalmological examination was unremarkable. Renal sonogram demonstrated normal-sized, symmetric kidneys without hydronephrosis or cysts. Urological studies including computed tomography were normal. The renal biopsy obtained at 3 years of age revealed glomeruli of normal size, with most glomeruli only exhibiting mild segmental mesangial cell proliferation ( Figure 2a). There was no glomerulosclerosis, tuft adhesions, or crescent formation affecting glomeruli. There was no cellular infiltrates or fibrosis evident in the tubulointerstitium or arterial vessels. Direct immunofluorescence revealed low-intensity, granular staining of IgG, IgM, and C3 in the mesangium. Electron microscopy demonstrated diffuse foot process effacement, with occasional glomerular basement membrane (GBM) alterations such as thinning, splitting, and some mesangial deposits, there by excluding a primary GBM or an immunocomplex disorder. Following the biopsy, she still had persistent nephrotic-range proteinuria ( urine protein-to-creatinine ratio, 3.8 mg/mg), although maintaining normal renal function. She was treated with oral prednisone (1 mg/kg daily for 4 weeks), but her proteinuria did not respond ( Figure 1b). Because of the unresponsiveness, cyclosporin (5 mg/kg daily) was started in addition to alternate-day predonisone (1 mg/kg). However, the proteinuria had still continued and the immunosuppressants were subsequently tapered off over the next 12 weeks. The patients had been thereafter treated with supportive antiproteinuric therapy. At 5 years of age, she still continued to havenephroticrange proteinuria ( urine protein-to-creatinine ratio, similar to 4.0 mg/mg). To explore the pathological basis of SRNS, a renal biopsy and genetic study was undertaken.
引用
收藏
页码:1209 / 1215
页数:7
相关论文
共 50 条
  • [31] Enalapril dosage in steroid-resistant nephrotic syndrome
    Arvind Bagga
    Basanagoud D. Mudigoudar
    Pankaj Hari
    Vandita Vasudev
    Pediatric Nephrology, 2004, 19 : 45 - 50
  • [32] Cyclosporine A and steroid therapy in childhood steroid-resistant nephrotic syndrome
    Tahar, Gargah
    Rachid, Lakhoua M.
    INTERNATIONAL JOURNAL OF NEPHROLOGY AND RENOVASCULAR DISEASE, 2010, 3 : 117 - 121
  • [33] Cyclosporine and steroid therapy in children with steroid-resistant nephrotic syndrome
    Yuko Hamasaki
    Norishige Yoshikawa
    Shinzaburo Hattori
    Satoshi Sasaki
    Kazumoto Iijima
    Koichi Nakanishi
    Takeshi Matsuyama
    Kenji Ishikura
    Nahoko Yata
    Tetsuji Kaneko
    Masataka Honda
    Pediatric Nephrology, 2009, 24 : 2177 - 2185
  • [34] Tacrolimus in steroid-resistant and steroid-dependent nephrotic syndrome
    Westhoff, TH
    Schmidt, S
    Zidek, W
    Beige, J
    van der Giet, M
    CLINICAL NEPHROLOGY, 2006, 65 (06) : 393 - 400
  • [35] Cyclosporine and steroid therapy in children with steroid-resistant nephrotic syndrome
    Hamasaki, Yuko
    Yoshikawa, Norishige
    Hattori, Shinzaburo
    Sasaki, Satoshi
    Iijima, Kazumoto
    Nakanishi, Koichi
    Matsuyama, Takeshi
    Ishikura, Kenji
    Yata, Nahoko
    Kaneko, Tetsuji
    Honda, Masataka
    PEDIATRIC NEPHROLOGY, 2009, 24 (11) : 2177 - 2185
  • [36] Use of rituximab in patients with steroid-dependent nephrotic syndrome and steroid-resistant nephrotic syndrome
    Liern, J. M.
    Mannotas, C.
    Bonani, P.
    Vallejo, G.
    PEDIATRIC NEPHROLOGY, 2016, 31 (10) : 1858 - 1858
  • [37] Management and Outcome of Steroid-Resistant Nephrotic Syndrome in Children
    Otukesh, Hasan
    Otukesh, Salman
    Mojtahedzadeh, Mona
    Hoseini, Rozita
    Fereshtehnejad, Seyed-Mohammad
    Fard, Azam Riahi
    Sadigh, Nader
    Behzadi, Ashkan Heshmatzade
    Javadi, Ramila
    Hooman, Nakissa
    Mehrazma, Mitra
    IRANIAN JOURNAL OF KIDNEY DISEASES, 2009, 3 (04) : 210 - 217
  • [38] PEPTIDE BIOMARKER SIGNATURES IN STEROID-RESISTANT NEPHROTIC SYNDROME
    Zurbig, Petra
    Ozaltin, Fatih
    Anarat, Ali
    Paripovic, Dusan
    Yilmaz, Alev
    Caliskan, Salim
    Jankauskiene, Augustina
    Trautmann, Agnes
    Mischak, Harald
    Schaefer, Franz
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2018, 33
  • [39] Chlorambucil therapy in children with steroid-resistant nephrotic syndrome
    Kari, JA
    Alkushi, A
    Alshaya, HO
    SAUDI MEDICAL JOURNAL, 2006, 27 (04) : 558 - 559
  • [40] Management of steroid-resistant nephrotic syndrome in children and adolescents
    Tullus, Kjell
    Webb, Hazel
    Bagga, Arvind
    LANCET CHILD & ADOLESCENT HEALTH, 2018, 2 (12): : 880 - 890